Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.33 |
| ▸ | ALB | P02768 | 2/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.33 |
| ▸ | DCK | P27707 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27503114 | 0.80 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL7165722 | 0.79 | PIK3CA (0.46) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL6855554 | 0.79 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL440453 | 0.78 | PDE3A (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL14125693 | 0.78 | FGFR1 (0.35) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL176469 | 0.77 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL28515026 | 0.77 | FGFR1 (0.34) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL27612127 | 0.76 | POLB (0.34) | LMNAMAPT | |
| SCHEMBL5356639 | 0.76 | FGFR1 (0.39) | FGFR1LMNATHRBMTORMDM2 | |
| SCHEMBL15798503 | 0.76 | PDE3A (0.33) | FGFR1LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999051761-A1 | IMPROVEMENTS IN OR RELATING TO NUCLEIC ACID SYNTHESIS AND SELECTION | MEDICAL RESEARCH COUNCIL (GB) | 1999-10-14 | — | — | WO | claimed |
| EP-0439550-A4 | DNA SEQUENCING BY MULTIPLE MIXED OLIGONUCLEOTIDE PROBES | — | 1991-09-25 | — | — | EP | claimed |
| EP-0439550-A1 | DNA SEQUENCING BY MULTIPLE MIXED OLIGONUCLEOTIDE PROBES | DNAX RESEARCH INSTITUTE OF MOLECULAR AND CELLULAR BIOLOGY, INC. (US) | 1991-08-07 | — | — | EP | claimed |
| WO-1990004652-A1 | DNA SEQUENCING BY MULTIPLE MIXED OLIGONUCLEOTIDE PROBES | DNAX RESEARCH INSTITUTE OF MOLECULAR AND CELLULAR BIOLOGY, INC. (US) | 1990-05-03 | — | — | WO | claimed |
| CN-117899048-A | Targeting lipid nanoparticle and preparation and application thereof | 上海交通大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-116059182-A | Nanoparticle, and preparation method and application thereof | 荣灿生物医药技术(上海)有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-2094863-B1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES, PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | PANAGENE INC (KR) | 2014-08-06 | — | — | EP | disclosed |
| US-8450469-B2 | Synthesis of peptide nucleic acids conjugated with amino acids and their application | PANAGENE INC. (KR) | 2013-05-28 | — | — | US | disclosed |
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | PANAGENE INC. (KR) | 2011-01-20 | — | — | US | disclosed |
| US-20100292471-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | PANAGENE INC. (KR) | 2010-11-18 | — | — | US | disclosed |
| EP-2094863-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES, PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | Panagene, Inc. (KR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075871-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES, PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | PANAGENE INC. (KR) | 2008-06-26 | — | — | WO | disclosed |
| WO-2004042078-A1 | NUCLEOTIDE SEQUENCE ANALYSIS BY QUANTIFICATION OF MUTAGENESIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2004-05-21 | — | — | WO | disclosed |
| WO-1999051761-A1 | IMPROVEMENTS IN OR RELATING TO NUCLEIC ACID SYNTHESIS AND SELECTION | MEDICAL RESEARCH COUNCIL (GB) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292471-A1 | PEPTIDE NUCLEIC ACID OLIGOMERS COMPRISING UNIVERSAL BASES,PREPARATION METHODS THEREOF, AND KITS, DEVICES AND METHODS FOR THE ANALYSIS, DETECTION OR MODULATION OF NUCLEIC ACIDS USING THE SAME | ADAR, POLM, POLRMT | FGFR1 2793/4885LMNA 527/4885THRB 3026/4885 |
| US-20110014715-A1 | Synthesis of Peptide Nucleic Acids Conjugated with Amino Acids and Their Application | CPSF6, RNGTT, DNPEP | FGFR1 2761/4885LMNA 1130/4885THRB 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.